TCRX — Tscan Therapeutics Income Statement
0.000.00%
- $309.25m
- $176.71m
- $21.05m
Annual income statement for Tscan Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 1.08 | 10.1 | 13.5 | 21 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 14.2 | 27.3 | 58.8 | 80.2 | 115 |
Operating Profit | -14.2 | -26.2 | -48.6 | -66.6 | -93.5 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -13.7 | -26.1 | -48.6 | -66.2 | -89.2 |
Net Income After Taxes | -13.7 | -26.1 | -48.6 | -66.2 | -89.2 |
Net Income Before Extraordinary Items | |||||
Net Income | -13.7 | -26.1 | -48.6 | -66.2 | -89.2 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -13.7 | -26.1 | -48.6 | -66.2 | -89.2 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.579 | -1.11 | -2.06 | -2.75 | -1.36 |
Dividends per Share |